Ann: OncoSil AGM CEO Presentation, page-94

What is the longest period @Abdi70 and @milsha77 have gone without being able to drink water? Due to severe nausea, obstruction or vomiting? The reality is this symptom alone of pancreatic cancer could result in hospital admissions which cost upwards of $5000 USD a day not to mention the pain and suffering inherent in severe nausea rendering ingestion of water impossible. The pancreas is a vital organ. If you have ever had even a moderate impairment of a vital organ you would understand the very clear reality of being so nauseous that ingestion of food or water is impossible and hospital admission is the only option.

The Oncosil device is made up of two parts, a honeycomb structure which is already FDA approved to deliver medicine to the eye in 4 products. The approvals allow doctors to inject upto 3 YEARS worth of potent medicine, in one injection into the eye safely. Two of the devices have been for sale for a number of years, and two have received approvals with reimbursement validation through Medicare permanent codes and securing pass through payment status, which is a financial incentive designed to increase the uptake and support payments by providers and patients.

The second aspect of the device is the radiotherapy which increases the strength of the available treatment immensely and the targeting potential, as it is available to be effective within the confines of the tumour 24hrs per day, as opposed to lower dose out of body radiation which must hit the cells during replication to be effective and using a much lower dose.

In regards to the time frame we are invested in a townhouse project that has taken since 2014, to get approval. Those are townhouses. This is a medical device/ similar in nature to a medicine, as it is effectively a combination of both delivery mechanism and radiotherapy. The website for oncosil clearly shows a pop-up indicating the device is not approved. The inference here is that the company is fielding many thousands of enquiries from recently diagnosed patients who have been told their tumour is unresectable or who are living out their life in pain. It may not occur to you the human impact of repeatedly having to tell suffering people that they cannot yet access innovative medical care. Perhaps the Directors enthusiasm doesn't stem from a desire to appease the market but the drive to get this offering to patients. Professions which have to impact pain on people or animals (dentists and vetinarians) have high rates of suicide. It would no doubt be difficult for management to repeatedly instruct staff 'not yet' 'reply not yet', when given the survival rates in this indication.

reduced fibrosis, chance of resection (chance of cure), clear margins post resection and the proven nature of the honeycomb device, pain relief (maybe the ability to gulp a glass of water again) devices proven safety in delivering large volumes of potent medicine into a delicate organ of the eye, and the previously approved and the ideal physical properties of the P32, are imho compelling.